Click on image to view larger version.

Figure 4 Coronary heart disease (CHD) event rates in secondary prevention trials (5 years in duration except the PROVE-IT study, which was 2 years) were directly proportional to low-density lipoprotein (LDL) cholesterol levels. The event rate is predicted to approach 0 at LDL of 30 mg/dl (8–12). 4S = Scandinavian Simvastatin Survival Study; CARE = Cholesterol And Recurrent Events trial; HPS = Heart Protection Study; LIPID = Long-term Intervention with Pravastatin In Ischemic Disease trial; PROVE-IT = PRavastatin Or atorVastatin Evaluation and Infection Therapy trial. Other abbreviations as in Figure 2.